Ampio updates Ampion regulatory progress

Ampio updates Ampion regulatory progress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) is providing an update of the regulatory and clinical path activities required to file a Biologics License Application (BLA) for Ampion... Read More

Monday November 12, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Mike Macaluso

Ampio Pharmaceuticals announces stock offering to raise $8M

Ampio Pharmaceuticals announces stock offering to raise $8M

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced the pricing of an underwritten public offering of 20 million shares of its common stock and warrants to purchase up to... Read More

Monday August 13, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals

Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain

Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) reported that the Phase 3 clinical trial of Ampion met its primary endpoint with 71% of Ampion treated patients meeting the... Read More

Friday December 15, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso

Ampio seeks to raise $6.75M through stock sale

Ampio seeks to raise $6.75M through stock sale

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it has entered into a securities purchase agreement with investors for the registered sale of approximately$6.75... Read More

Tuesday October 17, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals

Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion

Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) today announced the allowance of an important composition and methods patent in the U.S. complimenting a series of patents on Ampion... Read More

Tuesday August 8, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, Ampion

Ampio appoints Tom Chilcott as interim CEO

Ampio appoints Tom Chilcott as interim CEO

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) today announced it has not renewed the employment agreement of Gregory Gould , Ampio's chief financial officer, which expired on ... Read More

Tuesday June 13, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Gregory Gould, Tom Chilcott, Aytu BioScience

Ampio Pharmaceuticals selling $6.3M in stock to fund Ampion clinical tests

Ampio Pharmaceuticals selling $6.3M in stock to fund Ampion clinical tests

ENGLEWOOD -- A mpio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced it has entered into a securities purchase agreement with investors providing for the registered sale of approximately... Read More

Monday June 5, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion

Ampio initiates pivotal Ampion osteoarthritis trial

Ampio initiates pivotal Ampion osteoarthritis trial

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) announced it has begun a single injection study to meet the unmet medical need of treating the severe pain and loss of function... Read More

Monday May 1, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Dr. David Bar-Or, Chris Ehrlich, Michael Macaluso